Each week we highlight five things affecting the life sciences industry. Here’s the latest.
India–U.S. trade deal: Key takeaways
- Tariff reductions by the U.S. lowered duties on Indian exports from up to 50% down to 18%, improving competitiveness for India’s pharma and medtech sectors in the U.S., its largest export market.
- The agreement is seen as a strategic boost to India’s generics and biosimilars manufacturers, offering pricing relief amid global competition and supporting a broader supply chain strategy to reduce reliance on China, per Digital Health News.
FDA launches domestic drug manufacturing precheck program
- Reuters reports that the U.S. Food and Drug Administration has begun accepting requests for its new PreCheck pilot program, aiming to speed construction and review of U.S.-based drug manufacturing facilities and reduce regulatory burden.
- The two‑phase program prioritizes plants producing critical medications and offers enhanced FDA engagement to accelerate development and strengthen domestic drug supply.
Lawmaker questions FDA’s fast‑track drug voucher program
- Rep. Jake Auchincloss, a Massachusetts Democrat, raised concerns about the FDA’s National Priority Voucher program.
- He cited a lack of transparency and unclear legal authority since Congress never approved it, according to AP News.
AI-focused biotech files for IPO
- Just days after starting its Phase 3 trial, an artificial intelligence-focused biotech filed for an initial public offering positioning itself as the first AI‑focused biotech to reach late‑stage development while seeking capital to extend its limited one‑year cash runway, and could be one of the largest biotech IPOs in recent years, according to Endpoints News.
- The company aims to fund its lead asthma antibody and two oncology programs amid rising competition in AI‑driven protein design.
UK plans investment for life sciences growth
- The UK government announced a £1.5 billion investment through its national research body over four years to strengthen life sciences, aiming to accelerate research, innovation and health care breakthroughs.
- The plan also includes longer-term funding stability for key research institutions and support tied to related technologies such as AI, reports UKTN.
For more insights in life sciences, check out RSM’s industry outlook.
